Kim et al. reported that oral administration of chitosan attenuated bleomycin-induced pulmonary fibrosis in rats by reducing TGF-β1 and IFN-γ levels [96], which makes chitosan a promising gene vector for the treatment of pulmonary fibrosis. Here, IFNG is linked to pulmonary fibrosis.